Lidia Atienza-Cuevas

Lidia Atienza-Cuevas

Auto-generated profile, based on publicly available information

Lidia Atienza-Cuevas

Department of Pathology, Puerta del Mar University Hospital, 11009 Cadiz, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Expert Systems with Applications
Verified
Journal Article
Closed access
BTBlanca María Priego Torres
Blanca María Priego Torres
BLBarbara Lobato-Delgado
Barbara Lobato-Delgado
LALidia Atienza-Cuevas
Lidia Atienza-Cuevas
Daniel Sanchez-MorilloDaniel Sanchez-Morillo
Daniel Sanchez-Morillo

12 November 2019 in Scientific Reports
Verified
Journal Article
Open access
MHMercè Hereu
Mercè Hereu
Sara Ramos-RomeroSara Ramos-Romero
Sara Ramos-Romero
CBCristina Busquets
Cristina Busquets
LALidia Atienza
Lidia Atienza
SASusana Amézqueta
Susana Amézqueta
JTJosep Lluís Torres
Josep Lluís Torres
Food contains bioactive compounds that may prevent changes in gut microbiota associated with Westernized diets. The aim of this study is to explore the possible additive effects of d-fagomine and ω-3 PUFAs (EPA/DHA 1:1) on gut microbiota and related risk factors during early stages in the development of fat-induced pre-diabetes. Male Sprague Dawley (SD) rats were fed a standard diet, or a high-fat (HF) diet supplemented with d-fagomine, EPA/DHA 1:1, a combination of both, or neither, for 24 weeks. The variables measured were fasting glucose and glucose tolerance, plasma insulin, liver inflammation, fecal/cecal gut bacterial subgroups and short-chain fatty acids (SCFAs). The animals supplemented with d-fagomine alone and in combination with ω-3 PUFAs accumulated less fat than those in the non-supplemented HF group and those given only ω-3 PUFAs. The combined supplements attenuated the high-fat-induced incipient insulin resistance (IR), and liver inflammation, while increasing the cecal content, the Bacteroidetes:Firmicutes ratio and the populations of Bifidobacteriales. The functional effects of the combination of d-fagomine and EPA/DHA 1:1 against gut dysbiosis and the very early metabolic alterations induced by a high-fat diet are mainly those of d-fagomine complemented by the anti-inflammatory action of ω-3 PUFAs.

12 April 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
AEAntonio Santisteban Espejo
Antonio Santisteban Espejo
IFIrene Bernal Florindo
Irene Bernal Florindo
JPJose Perez-Requena
Jose Perez-Requena
LALidia Atienza-Cuevas
Lidia Atienza-Cuevas
JMJulia Moran-Sanchez
Julia Moran-Sanchez
MGMarcial Garcia-Rojo
Marcial Garcia-Rojo
Classic Hodgkin lymphoma (cHL) constitutes a B cell-derived neoplasm defined by a scarce tumoral population, termed Hodgkin and Reed–Sternberg (HRS) cells, submerged into a histologically heterogeneous microenvironment. The paucity of HRS cells has historically hampered genetic studies, rendering the identification of the recurrent genetic lesions and molecular pathways deregulated in this lymphoma difficult. The advent of high-throughput sequencing methods such as next-generation sequencing (NGS) could sensibly optimize the identification of the mutational landscape of cHL. However, there is no current consensus either in the design of panels for targeted NGS or in its most relevant clinical applications. In this work, we systematically review the current state of NGS studies of cHL, stressing the need for standardization both in the candidate genes to be analyzed and the bioinformatic pipelines. As different institutions have developed and implemented their own customized NGS-based protocols, to compare and systematically review the major findings of this ongoing research area could be of added value for centers that routinely perform diagnostic, monitoring and genotyping strategies in cHL samples. The results of this systematic review should contribute to the interdepartmental harmonization and achievement of a consensus in the current clinical applications of NGS studies of cHL.

15 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
AEAntonio Santisteban Espejo
Antonio Santisteban Espejo
JPJose Perez-Requena
Jose Perez-Requena
LALidia Atienza-Cuevas
Lidia Atienza-Cuevas
JMJulia Moran-Sanchez
Julia Moran-Sanchez
MFMaria del Carmen Fernandez-Valle
Maria del Carmen Fernandez-Valle
MGMarcial Garcia-Rojo
Marcial Garcia-Rojo
The prognostic impact of the presence of Epstein–Barr virus (EBV) in classical Hodgkin lymphoma (cHL) is controversial. Previous studies reported heterogeneous results, rendering difficult the clinical validation of EBV as a prognostic biomarker in this lymphoma. The objective of this study was to evaluate the survival impact of the expression of EBV Latent-Membrane Protein 1 (EBV-LMP1) in tumoral Hodgkin–Reed–Sternberg (HRS) cells of primary diagnostic samples of cHL. Formalin-Fixed Paraffin-Embedded (FFPE) lymph node samples from 88 patients with cHL were analyzed. Patients were treated with the standard first-line chemotherapy (CT) with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) followed by radiotherapy. The Kaplan–Meier method and the Cox proportional hazards model were used for carrying out the survival analysis. In order to investigate whether the influence of EBV was age-dependent, analyses were performed both for patients of all ages and for age-stratified subgroups. In bivariate analysis, the expression of EBV was associated with older age (p = 0.011), mixed cellularity subtype cHL (p < 0.001) and high risk International Prognostic Score (IPS) (p = 0.023). Overall survival (OS) and progression-free survival (PFS) were associated with the presence of bulky disease (p = 0.009) and advanced disease at diagnosis (p = 0.016). EBV-positive cases did not present a significantly lower OS and PFS in comparison with EBV-negative cases, for all ages and when stratifying for age. When adjusted for covariates, absence of bulky disease at diagnosis (HR: 0.102, 95% CI: 0.02–0.48, p = 0.004) and limited disease stages (I–II) (HR: 0.074, 95% CI: 0.01–0.47, p = 0.006) were associated with a significant better OS. For PFS, limited-disease stages also retained prognostic impact in the multivariate Cox regression (HR: 0.145, 95% CI: 0.04–0.57, p = 0.006). These results are of importance as the early identification of prognostic biomarkers in cHL is critical for guiding and personalizing therapeutic decisions. The prognostic role of EBV in cHL could be modulated by the type of CT protocol employed and interact with the rest of presenting features.

1 January 2018 in Autopsy Case Reports
Verified
Journal Article
Open access
PDF file
ASAntonio Segado-Arenas
Antonio Segado-Arenas
LALidia Atienza-Cuevas
Lidia Atienza-Cuevas
JBJosé Román Broullon-Molanes
José Román Broullon-Molanes
MRMoises Rodriguez-Gonzalez
Moises Rodriguez-Gonzalez
SLSimon Lubián López
Simon Lubián López
Autops Case Rep, vol.8, n4, e2018051, 2018

Verified
Journal Article
Open access
PDF file
AEAntonio Santisteban Espejo
Antonio Santisteban Espejo
IFIrene Bernal Florindo
Irene Bernal Florindo
PMPedro Montero-Pavon
Pedro Montero-Pavon
JPJose Perez-Requena
Jose Perez-Requena
LALidia Atienza-Cuevas
Lidia Atienza-Cuevas
MGMarcial Garcia-Rojo
Marcial Garcia-Rojo
Classic Hodgkin lymphoma (cHL) constitutes a B-cell neoplasm derived from germinal center lymphocytes. Despite high cure rates (80–90%) obtained with the current multiagent protocols, a significant proportion of cHL patients experience recurrences, characterized by a lower sensitivity to second-line treatments. The genomic background of chemorefractory cHL is still poorly understood, limiting personalized treatment strategies based on molecular features. In this study, using a targeted next-generation sequencing (NGS) panel specifically designed for cHL research, we compared chemosensitive and chemorefractory diagnostic tissue samples of cHL patients. Furthermore, we longitudinally examined paired diagnosis–relapsesamples of chemorefractory cHL in order to define patterns of dynamic evolution and clonal selection. Pathogenic variants in NOTCH1 and NOTCH2 genes frequently arise in cHL. Mutations in genes associated with epigenetic regulation (CREBBP and EP300) are particularly frequent in relapsed/refractory cHL. The appearance of novel clones characterized by mutations previously not identified at diagnosis is a common feature in cHL cases showing chemoresistance to frontline treatments. Our results expand current molecular and pathogenic knowledge of cHL and support the performance of molecular studies in cHL prior to the initiation of first-line therapies.